Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16357733 | 0.90 | ACACB (0.44) | HPGDACACBTDP1FFAR1ADAM17 | |
| SCHEMBL8218633 | 0.88 | PTGES (0.53) | ADAM17KMT2AMEN1PTGES | |
| SCHEMBL8417363 | 0.84 | HPGD (0.51) | HPGDTDP1ADAM17KMT2AMEN1 | |
| SCHEMBL8212396 | 0.75 | RAB9A (0.49) | HPGDADAM17KMT2AMEN1NPC1 | |
| SCHEMBL8418295 | 0.75 | AOC3 (0.60) | HPGDADAM17KMT2AMEN1PTGES | |
| SCHEMBL8216640 | 0.72 | NPSR1 (0.43) | HPGDACACBFFAR1KMT2AMEN1 | |
| SCHEMBL16357691 | 0.71 | NPSR1 (0.39) | FFAR1FFAR4NPC1RAB9ANPSR1 | |
| SCHEMBL5769172 | 0.70 | NPSR1 (0.64) | HPGDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL8212712 | 0.69 | ALDH1A1 (0.50) | HPGDADAM17KMT2AMEN1NPC1 | |
| SCHEMBL8216582 | 0.69 | PTPN11 (0.55) | KMT2AMEN1NPSR1PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283175-A1 | ANTIBACTERIAL COMPOSITIONS | ACHAOGEN, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| WO-2011005355-A1 | COMBINATIONS COMPRISING A LPXC INHIBITOR AND AN ANTIBIOTIC FOR USE IN THE TREATMENT OF INFECTIONS CAUSED BY GRAM-NEGATIVE BACTERIA | ACHAOGEN, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| US-7638513-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-7553864-B2 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION (US) | 2009-06-30 | — | — | US | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| WO-2007064732-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND MICROBIAL DISEASES | SCHERING CORPORATION (US) | 2007-06-07 | — | — | WO | disclosed |
| US-20070129378-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-06-07 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | MMP12, ADAMTS1, ADAM33 | HPGD 711/4885ACACB 322/4885TDP1 1915/4885 |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | MMP12, ADAMTS1, TNF | HPGD 493/4885ACACB 400/4885TDP1 2068/4885 |
| US-20070129378-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | MMP12, PCSK9, ALPI | HPGD 766/4885ACACB 360/4885TDP1 1840/4885 |
| US-20120283175-A1 | ANTIBACTERIAL COMPOSITIONS | LPXN, LCT, LPO | HPGD 1016/4885ACACB 996/4885TDP1 4340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.